First data from $JNJ's Phase 1/2a study will be available in September, according to Paul Stoffels.

Phase 3 trial could then begin in mid to late September, with preliminary data by end of 2020 or early 2021. 

$JNJ prepared to supply 1 billion doses in 2021, Stoffels said.